Annexon (ANNX) Retained Earnings (2019 - 2026)
Annexon (ANNX) posted quarterly Retained Earnings of $1.2 billion for Q1 2026, up 1281400.0% year-over-year from N/an in Q1 2025, and up 4020731.03% quarter-over-quarter from -$29000.0 in Q4 2025.
Annexon (ANNX) Retained Earnings (2019 - 2026) Analysis & Trends
Annexon's Retained Earnings history runs 8 years deep, the most recent figure standing at $1.2 billion for Q1 2026.
- In Q1 2026, Retained Earnings rose 1281400.0% year-over-year to $1.2 billion; the TTM figure through Mar 2026 stood at $1.2 billion (up 1281400.0% YoY), while the FY2025 annual figure was -$29000.0, up 100.0% from the prior year.
- Retained Earnings for Q1 2026 stood at $1.2 billion, up from -$29000.0 in the prior quarter.
- The five-year high for Retained Earnings was $1.2 billion in Q1 2026, with the low at -$869.1 million in Q3 2025.
- The 5-year median for Retained Earnings is -$368.8 million (2022), against an average of -$213.9 million.
- The sharpest annual moves came in 2025 and 2026: Retained Earnings plunged 914731.46% in 2025, then jumped 1281400.0% in 2026.
- Annexon's Retained Earnings stood at -$438.3 million in 2022, then slumped by 30.63% to -$572.5 million in 2023, then decreased by 24.14% to -$710.7 million in 2024, then jumped by 100.0% to -$29000.0 in 2025, then jumped by 4020731.03% to $1.2 billion in 2026.
- Business Quant data shows ANNX's Retained Earnings at $1.2 billion in Q1 2026, -$29000.0 in Q4 2025, and -$869.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Annexon | 1.00 Bn | 1.00 Bn | - | 1.20 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.20 Bn |
| Mar 31, 2026 | 1.17 Bn |
| Dec 31, 2025 | -29,000.00 |
| Sep 30, 2025 | -869.10 Mn |
| Jun 30, 2025 | -814.20 Mn |
| Mar 31, 2025 | -91,000.00 |
| Dec 31, 2024 | -710.70 Mn |
| Sep 30, 2024 | -662.10 Mn |
| Jun 30, 2024 | -89,000.00 |
| Mar 31, 2024 | -102,000.00 |
| Dec 31, 2023 | -572.50 Mn |
| Sep 30, 2023 | -544.60 Mn |
| Jun 30, 2023 | -512.10 Mn |
| Mar 31, 2023 | 691.96 Mn |
| Dec 31, 2022 | -438.26 Mn |
| Sep 30, 2022 | -406,000.00 |
| Jun 30, 2022 | -368.80 Mn |
| Mar 31, 2022 | -373,000.00 |
| Dec 31, 2021 | 528.37 Mn |
| Sep 30, 2021 | -75,000.00 |